Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program

MT Newswires Live

06/22

Traws Pharma (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.

Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.

The company said it expects a formal response from the regulator within 30 days of the resubmission.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2645022306"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645022306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645022306?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645022306","market":"us","top_or_hot":-1,"title":"Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.</p><p>Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.</p><p>The company said it expects a formal response from the regulator within 30 days of the resubmission.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.</p><p>Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.</p><p>The company said it expects a formal response from the regulator within 30 days of the resubmission.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645022306","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645022306","pubTimestamp":1782131035,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Traws Pharma  said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.The company said it expects a formal response from the regulator within 30 days of the resubmission.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TRAW":"TRAWS PHARMA"},"translate_title":"Traws Pharma表示正在开发流感预防计划的最新毒理学数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":1},"content_text":"Traws Pharma (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.The company said it expects a formal response from the regulator within 30 days of the resubmission.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}